Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • Seed Grant News
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Where to Begin
    • Caregivers & Families
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Resources →
      • NCCN Guidelines for Patients
      • Patient Support Tools
      • Create Your Health Care Team
      • Patient Health Diaries
      • Support Groups
      • Financial Aid
  • HOW YOU CAN HELP
    • Planned Giving
    • Donor-Advised Funds
    • Event Calendar
    • Get Inspired
    • Fundraising Resources
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • More Ways to Give →
      • You Can Help Funds
      • Host Your Own Event
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Ethan V Abel, PhD

Ethan V Abel, PhD

Ethan V. Abel, Ph.D.
Ethan V. Abel, Ph.D.
Assistant Professor
Molecular and Cellular Biology

Roswell Park Comprehensive Cancer Center
Buffalo, NY

Deciphering the role of the HNF1A-SKP2 axis in therapeutic response in pancreatic ductal adenocarcinoma

Overview

Aim: Therapy

Therapeutic resistance is a hallmark of pancreatic ductal adenocarcinoma (PDAC), and understanding the underlying mechanisms is essential to realizing effective treatments for this disease. Pancreatic cancer has the lowest survival rate of any major malignancy, largely due to resistance to conventional and targeted therapies. One such targeted therapy, MEK-inhibitors (MEKi), are used to block the signaling pathway of mutant KRAS, the most common driving mutation in PDAC; however, resistance to MEKi has limited their use in the clinic. The mechanisms driving resistance to MEKi are not well understood.

Another class of targeted therapies are BET-inhibitors (BETi), which target the epigenome to turn off the expression of cancer-driving genes. The mechanisms that determine response to BETi in PDAC are unknown, and understanding these mechanisms is important for predicting patient response and resistance. We have found that the novel oncogene, HNF1A, which regulates gene expression in PDAC, promotes resistance to MEKi. Additionally, HNF1A is eliminated by BETi and this appears critical for BETi function in PDAC.

In the context of both MEKi and BETi we found that HNF1A upregulates the expression of SKP2, an oncogene and important driver of cell growth. We hypothesize that this HNF1A-SKP2 “axis” is critical for resistance to MEKi and response to BETi. In this proposal, we will mechanistically explore how HNF1A regulates SKP2 while also exploring how HNF1A and SKP2 determine resistance and sensitivity of PDAC cells to MEKi and BETi. These studies will lead to a better understanding of how HNF1A and SKP2 control responsiveness to therapies and will shed light on how targeting these drivers can improve patient treatment options.

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Financial Information
  • Contact